EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Statin–Ezetimibe Attenuates Hepatic Inflammation and Fibrosis in a Diet- and Toxin-Induced Steatohepatitis Model, Associated with Macrophage NF-κB Inhibition

Seul Ki Han iD, Jin Suk Lee iD, Su Jung Park, Mi Ra Lee, Yu Jin Yi, Kangchan Choi iD, Soon Koo Baik, Moon Young Kim iD

Cells · 2026

DOI: 10.3390/cells15181700 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2026. Verfasst von Seul Ki Han und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea. Hauptthemen laut MEDLINE: NF-kappa B, Macrophages, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Ezetimibe. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Korean government, Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over 30% of adults globally; its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), has limited pharmacological options beyond the recently approved resmetirom. The statin–ezetimibe combination, widely co-prescribed for dyslipidemia in patients with MASH, significantly reduces hepatic fat versus statin monotherapy in the ESSENTIAL randomized trial, yet macrophage-driven mechanisms linking this lipid-lowering combination to hepatic inflammation and fibrosis remain poorly characterized. We investigated these mechanisms using in vivo and in vitro approaches.

Methods

Male C57BL/6 mice (n = 6/group; 6 groups) received a high-fat diet (HFD; 45% kcal) plus thioacetamide (TAA; 300 mg/kg twice-weekly, 8 weeks) to establish MASH with advanced fibrosis. Simvastatin (5 mg/kg) and/or Ezetimibe (10 mg/kg) were added to the diet for 4 weeks. Blinded hepatic histology (H&E, Picrosirius red, Oil Red-O), qPCR, immunohistochemistry, and Western blot were performed. Macrophage polarization and NF-κB nuclear translocation were assessed in RAW 264.7 cells and thioglycolate-elicited peritoneal macrophages by flow cytometry and immunofluorescence.

Results

Combination therapy significantly reduced steatosis, inflammation, and fibrosis versus HFD-TAA controls. Pro-inflammatory (IL-1β, IL-6, TNF-α, iNOS) and fibrosis-related (collagen-I, α-SMA, TGF-β1) markers were markedly suppressed (p < 0.01). In vitro, the combination reduced the proportion of iNOS+ macrophages to approximately 50% of the LPS control (normalized to each experiment), although statistical significance was not reached; monotherapies showed weaker and variable trends and inhibited NF-κB p65 nuclear translocation in cultured macrophages (Holm-adjusted p < 0.01); MAPK signaling was not significantly altered under the present conditions. Anti-fibrotic effects were consistent with a macrophage-mediated mechanism, with no direct stellate cell suppression observed by LX-2 assays.

Conclusions

Statin–Ezetimibe combination exerts anti-inflammatory and anti-fibrotic effects in a multi-hit murine model of MASH with advanced fibrosis associated with macrophage NF-κB inhibition in vitro and with reduced hepatic inflammatory signaling in vivo. These findings provide mechanistic rationale for the hepatic benefits of this widely used regimen in MASH patients with dyslipidemia, supporting its evaluation as a drug-repurposing strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NF-kappa BMacrophagesHydroxymethylglutaryl-CoA Reductase InhibitorsEzetimibeLiver CirrhosisFatty LiverInflammationNon-alcoholic Fatty Liver DiseaseAnimalsMaleMice, Inbred C57BLDiet, High-FatMiceDisease Models, AnimalLiverThioacetamideRAW 264.7 Cells

Stichwörter der Autor:innen

NF-κBezetimibehepatic fibrosismacrophage activationmetabolic dysfunction-associated steatohepatitisstatin

Substanzen

NF-kappa BHydroxymethylglutaryl-CoA Reductase InhibitorsEzetimibeThioacetamide

Autor:innen und Institutionen

  • Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea.
  • Regeneration Medicine Research Center, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea.
  • Cell Therapy and Tissue Engineering Center, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea.
  • Mitohormesis Research Center, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea.

ORCID-Profile: Seul Ki Han, Jin Suk Lee, Kangchan Choi, Moon Young Kim

Förderung

  • National Research Foundation of Korea
  • Korean government
  • Ministry of Education

Zitieren

APA

Han, S. K., Lee, J. S., Park, S. J., Lee, M. R., Yi, Y. J., Choi, K., Baik, S. K., & Kim, M. Y. (2026). Statin–Ezetimibe Attenuates Hepatic Inflammation and Fibrosis in a Diet- and Toxin-Induced Steatohepatitis Model, Associated with Macrophage NF-κB Inhibition. Cells. https://doi.org/10.3390/cells15181700

Vancouver

Han SK, Lee JS, Park SJ, Lee MR, Yi YJ, Choi K, et al. Statin–Ezetimibe Attenuates Hepatic Inflammation and Fibrosis in a Diet- and Toxin-Induced Steatohepatitis Model, Associated with Macrophage NF-κB Inhibition. Cells. 2026. doi:10.3390/cells15181700

BibTeX
@article{Han2026,
  author = {Han, Seul Ki and Lee, Jin Suk and Park, Su Jung and Lee, Mi Ra and Yi, Yu Jin and Choi, Kangchan and Baik, Soon Koo and Kim, Moon Young},
  title = {Statin–Ezetimibe Attenuates Hepatic Inflammation and Fibrosis in a Diet- and Toxin-Induced Steatohepatitis Model, Associated with Macrophage NF-κB Inhibition},
  journal = {Cells},
  year = {2026},
  doi = {10.3390/cells15181700}
}
Kostenlos starten →